REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026 at 2:00 p.m. PT in Dana Point, CA.
The event will be webcast live and later archived in the Investors section of Revelation Biosciences' website at www.RevBiosciences.com.
Positive
- None.
Negative
- None.
News Market Reaction – REVB
In the Mar 24 session, REVB declined 8.20%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Conference participation | Neutral | -1.6% | Announcement of Roth Conference attendance and fireside chat scheduling. |
| Feb 26 | Earnings and update | Positive | -0.8% | Reported FY 2025 results, cash of $10.7M, Gemini progress and runway. |
| Jan 26 | Reverse stock split | Negative | -14.8% | 1-for-4 reverse split to address Nasdaq minimum bid requirement. |
| Jan 23 | Warrant inducement | Negative | -24.4% | Reduced-price warrant exercise and issuance of new Class J warrants. |
| Jan 21 | Regulatory pathway | Positive | -10.1% | FDA agreement on single adaptive Phase 2/3 Gemini AKI study of ~300 patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and financing news has previously seen negative price reactions, while structurally dilutive events also aligned with sell-offs.
Over the last few months, REVB has reported several key events, including an FDA-agreed single adaptive Phase 2/3 Gemini study for AKI on Jan 21, 2026, a warrant inducement generating roughly $11 million, and a 1-for-4 reverse split effective Jan 28, 2026. Earnings on Feb 26, 2026 highlighted $10.7M year-end cash and Gemini progress. A prior Roth Conference participation announcement on Mar 19, 2026 preceded this reminder, framing today’s news as incremental rather than a new catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.
The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com, after the meeting.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences Inc.
View the original press release on ACCESS Newswire